Nu-Med Plus Inc. (NUMD:OTC.MKTS) applied for a patent for its newly developed device that can deliver nitric oxide to stored blood products before they are transfused into a patient, according to a news release. The delivery can be done during or after the drawing of blood.
Using the device in this way should make stored blood products last longer and transfusions safer, according to the company. Recently studies have shown that the longer blood is stored, the more it loses nitric oxide. When blood is low in nitric oxide, it can cause side effects, such as hypoxia, infection and heart failure, in someone infused with it. The Federal Drug Administration currently prohibits the use of blood in transfusions that has been stored longer than 42 days.
The company notes that this research also suggests that pretreating banked blood products with nitric oxide allows for transfer of oxygen via the blood during a transfusion.
"A blood transfusion is one of the most common medical procedures in the world, and we believe this new Nu-Med Plus nitric oxide delivery technology will decrease the risks and increase the life-saving potential of blood transfusions," Nu-Med CEO Jeff Robins said in the release. Every year, more than 4 million Americans have a blood transfusion; 300,000 of those transfused individuals receive one or more blood units that have been stored for 30-plus days.
Nu-Med Plus stated that it intends to conduct further studies on its new device, testing its efficacy.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
